Apr 2 |
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Apr 2 |
Earnings Scheduled For April 2, 2024
|
Apr 1 |
AIM ImmunoTech FY 2023 Earnings Preview
|
Mar 26 |
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
|
Mar 25 |
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|
Mar 25 |
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
|
Mar 22 |
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
|
Mar 15 |
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
|
Feb 29 |
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
|
Feb 14 |
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
|